CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Xagena Salute
Dermabase.it

ESC 2019 - Implantable cardioverter-defibrillator associated with lower mortality in heart failure


Implantable cardioverter-defibrillator ( ICD ) use is associated with reduced short- and long-term mortality in patients with heart failure.

Patients with heart failure are at increased risk of potentially lethal ventricular arrhythmias and sudden cardiac death.
ICDs are used to correct these arrhythmias and prevent sudden death.

ESC guidelines recommend an ICD for primary prevention in symptomatic patients with heart failure with reduced ejection fraction ( HFrEF ), provided they are expected to survive substantially longer than one year with good functional status.

Most randomised trials on ICD use for primary prevention of sudden cardiac death in HFrEF enrolled patients more than 20 years ago.
However, characteristics and management of HFrEF have substantially changed since then and it is not known whether ICD improves outcome on top of contemporary treatments.
Furthermore, it is unclear whether ICD use is equally beneficial in subgroups such as both women and men or older and younger patients.

The study has investigated the association between ICD use and all-cause mortality in a contemporary HFrEF cohort with a focus on subgroups.
The study population was compiled from patients in the Swedish Heart Failure Registry ( SwedeHF ) fulfilling ESC criteria for primary prevention ICD use.
Propensity score matching was used to account for differences at baseline.

Of 16,702 eligible patients in SwedeHF, 1,599 ( 9.6% ) had an ICD.
Among patients from SwedeHF fulfilling ESC criteria for primary prevention ICD use, less than 10% had the device.
ICD use in Sweden is known to be lower than in other European countries ( e.g. Germany or Italy ). This could be because most heart failure patients are seen by primary care physicians and geriatricians who could be less inclined to accept device therapy and have a higher perception of contraindications compared to cardiologists.

The propensity matched population consisted of 1,296 ICD users and 1,296 patients without an ICD.

The researchers found that ICD use was associated with a 26% relative reduction in the risk of all-cause mortality at one year and a 13% relative reduction in the risk of all-cause mortality at five years.
The five-year absolute risk reduction with ICD use was 3.1% leading to 33 patients needing to be treated to prevent one death in five years.

The short-term and long-term mortality benefit was consistent across subgroups, such as patients with or without ischaemic heart disease, males and females, patients under 75 and 75 and older, those enrolled earlier versus later in SwedeHF and thus receiving less or more contemporary treatment, and also for patients with or without cardiac resynchronisation therapy.

In conclusion, the study found that primary prevention ICD was associated with reduced short-term and long-term all-cause mortality in HFrEF overall and in several subgroups.
The findings support the current recommendations and call for better implementation of ICD use in clinical practice.

The study was published in Circulation. ( Xagena )

Source: European Society of Cardiology ( ESC ) Congress 2019

XagenaMedicine_2019



Indietro